Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The long-term goals of this study are to foster development and dissemination of
evidence-based behavioral and pharmacological treatments to reduce HIV transmission,
injection drug use (IDU), and heroin use in Russia. This study will examine the effects of
combining behavioral therapy with naltrexone pharmacotherapy for the treatment of opiate
dependence and reduction of HIV risks in opiate dependent individuals. Specifically the study
will determine whether extended-release injection naltrexone has greater efficacy and is more
cost-effective than oral naltrexone maintenance, whether behavioral drug and HIV risk
reduction counseling (BDRC) combined with brief, medical management (MM) has greater efficacy
and is more cost-effective than MM only, and whether particular combinations of medication
formulation and counseling (MM only or MM plus BDRC) have greater efficacy or are more
cost-effective than other combinations.
Phase:
Phase 3
Details
Lead Sponsor:
Yale University
Collaborators:
National Institute on Drug Abuse (NIDA) St. Petersburg State Pavlov Medical University